SurModics, Inc, a leading provider of drug delivery and surface modification technologies to the healthcare industry, introduced its StabilBlot Buffer (Protein-Free) product at the American Association for Clinical Chemistry (AACC) - Clinical Lab Expo in Anaheim, California.

StabilBlot buffer is the newest member of SurModics' Stabil family of quality, market-proven immunodiagnostic reagents. StabilBlot buffer was developed for blocking and antibody dilution in blotting applications. Data indicate that StabilBlot buffer significantly reduces background and increases signal in western blot applications. StabilBlot buffer is protein-free to minimize cross-reactivity; an excellent blocking buffer that significantly reduces background; used for nitrocellulose and polyvinylidene fluoride (PVDF) membranes; strongly recommended as an antibody diluent; and compatible with biotinylated antibodies

"This newest addition to SurModics' line of Stabil immunodiagnostic reagents demonstrates the flexibility of our capabilities to support the in vitro diagnostics industry," said Phil Ankeny, Interim CEO of SurModics. "SurModics remains committed to developing additional products based on this technology, enabling us to better serve our customers' needs."

SurModics' vision is to extend and improve the lives of patients through technology innovation. The company partners with the world's foremost medical device, pharmaceutical and life science companies to develop and commercialize innovative products that result in improved diagnosis and treatment for patients.